Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health’s rise from start-up to public telehealth leader is powered by one metric investors can’t ignore: subscriber retention across dermatology, mental-health and primary-care lines. That data lives deep inside each SEC filing.
Stock Titan surfaces exactly what matters. Our AI engine turns the dense language of a Hims & Hers Health annual report 10-K simplified into plain-English insights on fulfillment margins, privacy compliance costs and segment revenue. Need the latest Hims & Hers Health quarterly earnings report 10-Q filing? It arrives here in real time, alongside concise commentary that links prescription growth to cash-flow swings. Material developments—regulatory shifts, pharmacy partnerships, class-action updates—trigger a Hims & Hers Health 8-K material events explained snapshot within minutes.
Want to monitor management moves? Our alerts flag every Hims & Hers Health Form 4 insider transactions real-time so you can compare option exercises against marketing-spend disclosures. The page also answers common searches such as “Hims & Hers Health insider trading Form 4 transactions” and “Hims & Hers Health proxy statement executive compensation,” pairing raw documents with readable summaries.
- AI-powered digests that make understanding Hims & Hers Health SEC documents with AI straightforward
- Cross-links to Hims & Hers Health earnings report filing analysis for trend tracking
- Downloadable exhibits covering Hims & Hers Health executive stock transactions Form 4
Stop wading through 300 pages; let Stock Titan transform complex disclosures into investable clarity.
Franklin Financial Services Corporation (FRAF) filed a Form 4 disclosing that director Daniel J. Fisher acquired 313 common shares on 06/23/2025 at an implied price of $34.60 per share, totaling roughly $10.8 thousand. The shares were issued in lieu of cash compensation for a portion of Fisher’s board fees. Following the transaction, Fisher directly owns 29,276 shares, a figure that includes previously reported unvested restricted stock units. No derivative securities were involved.
The filing represents a routine compensation-related share issuance rather than an open-market purchase, but it still modestly increases insider equity alignment without altering control dynamics or signaling material changes to FRAF’s capital structure.
Hims & Hers Health (HIMS) Chief Financial Officer Oluyemi Okupe executed a planned sale of 23,107 shares of Class A Common Stock on June 23, 2025, at an average weighted price of $47.2483 per share (range: $47.15 - $47.43).
Following the transaction, Okupe's holdings include:
- 63,222 shares held directly
- 70,575 shares held indirectly through the Oluyemi Okupe Separate Property Trust
The sale was conducted under a Rule 10b5-1 trading plan established on May 31, 2024, demonstrating pre-planned, compliant insider trading activity. This transaction represents a partial reduction of the CFO's direct holdings while maintaining significant equity stake in the company through both direct and trust ownership.
A Form 144 filing from Hims & Hers Health reveals a proposed sale of 69,431 shares of common stock with an aggregate market value of $2,914,713.38. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 23, 2025.
The securities being sold were acquired through multiple compensation events:
- 37,186 shares from stock options (February 2022)
- 9,138 RSUs (June 2024)
- 23,107 RSUs (June 2025, across three grants)
The filing also discloses previous sales by Oluyemi Okupe over the past 3 months, totaling approximately 45,923 shares between April-May 2025, with total gross proceeds of about $1.98 million. These transactions demonstrate a consistent pattern of insider sales, with most individual transactions ranging from ~1,000 to ~9,200 shares.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
What is the primary focus of Hims & Hers Health Inc?
How does the company deliver its healthcare services?
What types of products and services does Hims & Hers offer?
How does Hims & Hers differentiate itself in the competitive digital healthcare market?
What revenue streams support its business model?
How does Hims & Hers ensure consumer trust in its platform?
Who is the target audience for Hims & Hers Health Inc?
